Lexaria Bioscience (NASDAQ:LEXX) Stock Price Down 9.6% – Here’s What Happened

Posted by George Bondi on Sep 16th, 2026

Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report)’s stock price was down 9.6% on Tuesday . The company traded as low as $2.98 and last traded at $3.21. Approximately 123,674 shares traded hands during mid-day trading, an increase of 12% from the average daily volume of 110,026 shares. The stock had previously closed at $3.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $22.50.

View Our Latest Report on LEXX

Lexaria Bioscience Stock Down 9.6%

The company has a market cap of $5.30 million, a P/E ratio of -0.63 and a beta of 0.50. The business has a 50-day moving average price of $8.62 and a two-hundred day moving average price of $10.01.

Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) last issued its earnings results on Monday, July 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). As a group, sell-side analysts expect that Lexaria Bioscience Corp. will post -4.05 EPS for the current fiscal year.

About Lexaria Bioscience

(Get Free Report)

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.